AU2016263598A1 - Methods and kits for treating depression - Google Patents

Methods and kits for treating depression Download PDF

Info

Publication number
AU2016263598A1
AU2016263598A1 AU2016263598A AU2016263598A AU2016263598A1 AU 2016263598 A1 AU2016263598 A1 AU 2016263598A1 AU 2016263598 A AU2016263598 A AU 2016263598A AU 2016263598 A AU2016263598 A AU 2016263598A AU 2016263598 A1 AU2016263598 A1 AU 2016263598A1
Authority
AU
Australia
Prior art keywords
esketamine
phase
patient
induction phase
dosage unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016263598A
Other languages
English (en)
Other versions
AU2016263598A8 (en
Inventor
Ivo CAERS
Ella DALY
Wayne C. Drevets
Jaskaran Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2016263598A1 publication Critical patent/AU2016263598A1/en
Publication of AU2016263598A8 publication Critical patent/AU2016263598A8/en
Priority to AU2021215155A priority Critical patent/AU2021215155A1/en
Priority to AU2023237026A priority patent/AU2023237026A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016263598A 2015-05-20 2016-05-20 Methods and kits for treating depression Abandoned AU2016263598A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021215155A AU2021215155A1 (en) 2015-05-20 2021-08-11 Methods and kits for treating depression
AU2023237026A AU2023237026A1 (en) 2015-05-20 2023-09-25 Methods and kits for treating depression

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20
US62/164,026 2015-05-20
PCT/US2016/033404 WO2016187491A1 (en) 2015-05-20 2016-05-20 Methods and kits for treating depression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021215155A Division AU2021215155A1 (en) 2015-05-20 2021-08-11 Methods and kits for treating depression

Publications (2)

Publication Number Publication Date
AU2016263598A1 true AU2016263598A1 (en) 2017-11-23
AU2016263598A8 AU2016263598A8 (en) 2017-11-30

Family

ID=57320901

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016263598A Abandoned AU2016263598A1 (en) 2015-05-20 2016-05-20 Methods and kits for treating depression
AU2021215155A Abandoned AU2021215155A1 (en) 2015-05-20 2021-08-11 Methods and kits for treating depression
AU2023237026A Abandoned AU2023237026A1 (en) 2015-05-20 2023-09-25 Methods and kits for treating depression

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021215155A Abandoned AU2021215155A1 (en) 2015-05-20 2021-08-11 Methods and kits for treating depression
AU2023237026A Abandoned AU2023237026A1 (en) 2015-05-20 2023-09-25 Methods and kits for treating depression

Country Status (20)

Country Link
US (1) US20160338977A1 (enExample)
EP (1) EP3297618A4 (enExample)
JP (1) JP2018515557A (enExample)
KR (1) KR20180008634A (enExample)
CN (1) CN107735081A (enExample)
AU (3) AU2016263598A1 (enExample)
CA (1) CA2986477A1 (enExample)
CL (1) CL2017002904A1 (enExample)
CO (1) CO2017011564A2 (enExample)
DO (1) DOP2017000268A (enExample)
EA (1) EA201792545A1 (enExample)
EC (1) ECSP17077930A (enExample)
GT (1) GT201700246A (enExample)
HK (1) HK1252937A1 (enExample)
IL (1) IL255463A (enExample)
MA (1) MA42135A (enExample)
MX (1) MX2017014797A (enExample)
PE (1) PE20180260A1 (enExample)
PH (1) PH12017502103A1 (enExample)
WO (1) WO2016187491A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
SG11202005896WA (en) * 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) * 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
EP3934632A4 (en) * 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
EP4021432A4 (en) * 2019-08-28 2023-08-16 Janssen Pharmaceuticals, Inc. ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
WO2021242504A1 (en) * 2020-05-28 2021-12-02 Janssen Pharmaceuticals, Inc. Methods for treating depression
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
KR20220044380A (ko) * 2013-04-12 2022-04-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
EP3193853A1 (en) * 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION

Also Published As

Publication number Publication date
DOP2017000268A (es) 2018-04-15
WO2016187491A1 (en) 2016-11-24
GT201700246A (es) 2019-07-29
PE20180260A1 (es) 2018-02-05
EA201792545A1 (ru) 2018-05-31
HK1252937A1 (zh) 2019-06-06
JP2018515557A (ja) 2018-06-14
CA2986477A1 (en) 2016-11-24
PH12017502103A1 (en) 2018-05-07
EP3297618A1 (en) 2018-03-28
CL2017002904A1 (es) 2018-04-20
MX2017014797A (es) 2018-02-15
ECSP17077930A (es) 2018-02-28
US20160338977A1 (en) 2016-11-24
MA42135A (fr) 2018-03-28
CN107735081A (zh) 2018-02-23
EP3297618A4 (en) 2019-01-23
KR20180008634A (ko) 2018-01-24
IL255463A (en) 2018-01-31
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
AU2021215155A1 (en) 2021-09-02
CO2017011564A2 (es) 2018-04-19

Similar Documents

Publication Publication Date Title
AU2023237026A1 (en) Methods and kits for treating depression
US20250255835A1 (en) Methods For The Treatment Of Depression
CA3086478A1 (en) Esketamine for the treatment of depression
CN104519878A (zh) 用于治疗顽固性或难治性抑郁症的艾氯胺酮
US20240325296A1 (en) Esketamine for the treatment of depression
AU2014281414A1 (en) Use of high dose pridopidine for treating Huntington's disease
US20200009081A1 (en) Delivery Of Esketamine For The Treatment Of Depression
Ventura et al. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial
CA3153856A1 (en) Intranasal administration of esketamine
AU2016203771A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
Farmer et al. Pharmacological intervention for disruptive behaviors in intellectual and developmental disabilities: the glass is half full
Amsterdam et al. Once-versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study
Sanacora Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants.
EP4687860A1 (en) Esketamine for use in the treatment of depression
AU2013201492A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AU2013203567A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
Trinza DA US FDA Approved for
TW201002719A (en) Treatment of attention-deficit/hyperactivity disorder
Lubetsky Benjamin L. Handen, Tiberiu Bodea, Rameshwari V. Tumuluru, and

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 46 , PAGE(S) 6665 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME JANSSEN PHARMACEUTICA NV, APPLICATION NO. 2016263598, UNDER INID (72) REMOVE CO-INVENTOR SHIRTZ, JOSEPH; UNDER INID (72) ADD CO-INVENTOR SINGH, JASKARAN

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application